Filiz Bakar1, Uğur Unlütürk, Nilgün Başkal, Serpil Nebioğlu. 1. Department of Biochemistry (F.B., S.N.), School of Pharmacy, and Department of Endocrinology and Metabolism (U. Ü., N.B.), School of Medicine, Ankara University, 06100 Ankara, Turkey.
Abstract
BACKGROUND: Annexin V (AnxV) has potent anticoagulant properties and regulatory functions for apoptosis and inflammation. Antibodies against annexin V (anti-AnxVs) may inhibit AnxV functions, leading to thrombosis during autoimmune diseases. Type 1 diabetes is an autoimmune disease and related with an ongoing autoimmune inflammation and thrombotic complications. There is no study evaluating anti-AnxVs/AnxV in a disease setting. OBJECTIVE: The aim of this study was to evaluate the status of AnxV and anti-AnxVs in patients with type 1 diabetes. METHODS: One hundred twenty-one patients with type 1 diabetes and 92 healthy controls were included in this study. Serum levels of AnxV and anti-AnxVs and expression of the AnxV gene and its common polymorphism in Kozak sequence (-1C>T) were studied. As a functional assay, the binding capacity of AnxV to platelets was evaluated. RESULTS: As compared with controls, type 1 diabetic patients had significantly low serum AnxV levels and AnxV gene expression. The number of anti-AnxV positivity and their serum levels were significantly higher in type 1 diabetic patients than controls. AnxV binding to platelets were significantly decreased in the type 1 diabetic patients. The frequencies of the -1C>T polymorphism of AnxV gene did not differ between groups. CONCLUSIONS: This study demonstrated the significant changes in AnxV levels and its function in type 1 diabetic patients. These results support the hypothesis that the defective AnxV system may have a role in ongoing autoimmune activity and the development of thrombotic complications in type 1 diabetes. Further studies are necessary to elucidate the clinical impact of anti-AnxVs and dysregulated AnxV function in type 1 diabetes.
BACKGROUND:Annexin V (AnxV) has potent anticoagulant properties and regulatory functions for apoptosis and inflammation. Antibodies against annexin V (anti-AnxVs) may inhibit AnxV functions, leading to thrombosis during autoimmune diseases. Type 1 diabetes is an autoimmune disease and related with an ongoing autoimmune inflammation and thrombotic complications. There is no study evaluating anti-AnxVs/AnxV in a disease setting. OBJECTIVE: The aim of this study was to evaluate the status of AnxV and anti-AnxVs in patients with type 1 diabetes. METHODS: One hundred twenty-one patients with type 1 diabetes and 92 healthy controls were included in this study. Serum levels of AnxV and anti-AnxVs and expression of the AnxV gene and its common polymorphism in Kozak sequence (-1C>T) were studied. As a functional assay, the binding capacity of AnxV to platelets was evaluated. RESULTS: As compared with controls, type 1 diabeticpatients had significantly low serum AnxV levels and AnxV gene expression. The number of anti-AnxV positivity and their serum levels were significantly higher in type 1 diabeticpatients than controls. AnxV binding to platelets were significantly decreased in the type 1 diabeticpatients. The frequencies of the -1C>T polymorphism of AnxV gene did not differ between groups. CONCLUSIONS: This study demonstrated the significant changes in AnxV levels and its function in type 1 diabeticpatients. These results support the hypothesis that the defective AnxV system may have a role in ongoing autoimmune activity and the development of thrombotic complications in type 1 diabetes. Further studies are necessary to elucidate the clinical impact of anti-AnxVs and dysregulated AnxV function in type 1 diabetes.
Authors: Alessandro Iannaccone; Francesco Giorgianni; David D New; T J Hollingsworth; Allison Umfress; Albert H Alhatem; Indira Neeli; Nataliya I Lenchik; Barbara J Jennings; Jorge I Calzada; Suzanne Satterfield; Dennis Mathews; Rocio I Diaz; Tamara Harris; Karen C Johnson; Steve Charles; Stephen B Kritchevsky; Ivan C Gerling; Sarka Beranova-Giorgianni; Marko Z Radic Journal: PLoS One Date: 2015-12-30 Impact factor: 3.240
Authors: Ajibola Adedayo; Ayobami Eluwole; Fasika Tedla; Arye Kremer; Muhammad Khan; Nicole Mastrogiovanni; Carl Rosenberg; Paul Dreizen; John La Rosa; Louis Salciccioli; Mohamed Boutjdir; Mary Ann Banerji; Clinton Brown; Jason Lazar; Moro Salifu; Ahmed Bakillah Journal: Biomedicines Date: 2022-07-28